- Home
- REZI vs CPRX Comparison
REZI vs CPRX Comparison
Compare REZI & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REZI | CPRX |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.9B |
| IPO Year | 2018 | 2006 |
Fundamental Metrics
Financial Performance| Metric | REZI | CPRX |
|---|---|---|
| Price | $30.38 | $31.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $39.67 | $35.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | 0.17 | ★ 0.50 |
| Revenue | ★ $7,472,000,000.00 | $119,072,803.00 |
| Revenue This Year | $6.81 | $9.20 |
| Revenue Next Year | $3.62 | $10.51 |
| P/E Ratio | $180.35 | ★ $62.94 |
| Revenue Growth | 10.52 | ★ 16.39 |
| 52 Week Low | $23.12 | $19.05 |
| 52 Week High | $45.29 | $32.56 |
Technical Indicators
Market Signals| Indicator | REZI | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 70.75 |
| Support Level | $29.11 | $31.25 |
| Resistance Level | $33.09 | $32.56 |
| Average True Range (ATR) | 1.36 | 0.04 |
| MACD | 0.11 | -0.08 |
| Stochastic Oscillator | 23.03 | 75.00 |
Price Performance
Historical ComparisonAbout REZI Resideo Technologies Inc.
Resideo Technologies Inc is a manufacturer and developer of technology-driven products and components that provide critical comfort, energy management, and safety and security solutions. The company has two reportable segments; Products and Solutions segment offers temperature and humidity control, energy products and solutions, water and air solutions, smoke and carbon monoxide detection home safety products, security panels, sensors, peripherals, wire and cable, communications devices, video cameras, other home-related lifestyle convenience solutions; and ADI Global Distribution segment includes wholesale distributor of low-voltage security products including access control, fire detection, security, and video products. It derives majority of its revenue from the United States.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.